{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T18:59:48Z","timestamp":1785178788055,"version":"3.55.0"},"reference-count":50,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,7,18]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>The expedited approval of mpox vaccines is critical to addressing this public health emergency. Building on the practice in approving COVID-19 vaccines, this analysis investigates the regulatory pathways used to accelerate vaccine approvals and their implications for mpox vaccine development. The study highlights the regulatory frameworks of the WHO Emergency Use Listing, the U.S. Food and Drug Administration Emergency Use Authorisation, the European Medicines Agency Conditional Marketing Authorisation and Japan\u2019s Pharmaceuticals and Medical Devices Agency Emergency Approval. A comparative analysis of these pathways reveals differences in application conditions, data requirements, review timelines and post-approval obligations. The study also draws key lessons from the case analysis of COVID-19 vaccine approvals, providing additional insights for the approval of mpox vaccines. Our study underscores the importance of maintaining rigorous regulatory standards while expediting vaccine development and identifies fit-for-purpose strategies to enhance global preparedness for future public health crises, ensuring the availability of safe, effective and high-quality vaccines.<\/jats:p>","DOI":"10.1136\/bmjgh-2024-018517","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T09:30:22Z","timestamp":1755163822000},"page":"e018517","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Accelerating the approval of mpox vaccines based on lessons learnt from COVID-19 vaccines through the lens of regulatory science"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-7101","authenticated-orcid":false,"given":"Shanshan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Global Health, Peking University, Beijing, China"},{"name":"Institute for Global Health and Development, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Global Health, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Global Health, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianen","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Global Health, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4600-8644","authenticated-orcid":false,"given":"Ming","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Global Health, Peking University, Beijing, China"},{"name":"Institute for Global Health and Development, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2025081402301320000_10.8.e018517.1","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa227","article-title":"Public health emergencies of international concern: a historic overview","volume":"27","author":"Wilder-Smith","year":"2020","journal-title":"J Travel Med"},{"key":"2025081402301320000_10.8.e018517.2","first-page":"310","article-title":"Development of mRNA vaccines in response to the Public Health Emergency of International Concern","volume":"5","author":"Qing","year":"2024","journal-title":"Synth Biol"},{"key":"2025081402301320000_10.8.e018517.3","unstructured":"Stevens H , Debackere K , Goldman M , et al . Vaccines: accelerating innovation and access. global challenges report. Geneva World Intellectual Property Organization; 2017. Available: https:\/\/www.wipo.int\/edocs\/pubdocs\/en\/wipo_pub_gc_16.pdf"},{"key":"2025081402301320000_10.8.e018517.4","unstructured":"World Health Organization . Regulation and prequalification. Available: https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety [Accessed 16 Jun 2025]."},{"key":"2025081402301320000_10.8.e018517.5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5582\/ddt.2021.01064","article-title":"Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021","volume":"15","author":"Cui","year":"2021","journal-title":"DD&T"},{"key":"2025081402301320000_10.8.e018517.6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/all.14868","article-title":"Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID\u201019 vaccines in Europe","volume":"77","author":"Wagner","year":"2022","journal-title":"Allergy"},{"key":"2025081402301320000_10.8.e018517.7","first-page":"741","article-title":"FDA\u2019s Accelerated Approval, Emergency Use Authorization, and Pre-Approval Access: Considerations for Use in Public Health Emergencies and Beyond","volume":"23","author":"Coughlin","year":"2022","journal-title":"NC JL & Tech"},{"key":"2025081402301320000_10.8.e018517.8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1080\/17441692.2021.1938170","article-title":"Forty days of regulatory emergency use authorisation of COVID-19 vaccines: Interfacing efficacy, hesitancy and SDG target 3.8","volume":"16","author":"Nhamo","year":"2021","journal-title":"Glob Public Health"},{"key":"2025081402301320000_10.8.e018517.9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3390\/vaccines9080901","article-title":"The Relationship between US Adults\u2019 Misconceptions about COVID-19 Vaccines and Vaccination Preferences","volume":"9","author":"Kreps","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2025081402301320000_10.8.e018517.10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.amjmed.2021.02.004","article-title":"Debunking mRNA Vaccine Misconceptions\u2014An Overview for Medical Professionals","volume":"134","author":"Hitti","year":"2021","journal-title":"Am J Med"},{"key":"2025081402301320000_10.8.e018517.11","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2009.0041"},{"key":"2025081402301320000_10.8.e018517.12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.1","article-title":"FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes","volume":"97","author":"Kesselheim","year":"2015","journal-title":"Clin Pharma and Therapeutics"},{"key":"2025081402301320000_10.8.e018517.13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.vaccine.2020.12.048","article-title":"Timing of COVID-19 vaccine approval and endorsement by public figures","volume":"39","author":"Bokemper","year":"2021","journal-title":"Vaccine (Auckl)"},{"key":"2025081402301320000_10.8.e018517.14","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/S1473-3099(20)30923-3","article-title":"The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials","volume":"21","author":"Singh","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2025081402301320000_10.8.e018517.15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/bcp.12940","article-title":"Characteristics and follow\u2010up of postmarketing studies of conditionally authorized medicines in the EU","volume":"82","author":"Hoekman","year":"2016","journal-title":"Brit J Clinical Pharma"},{"key":"2025081402301320000_10.8.e018517.16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11606-018-4779-x","article-title":"Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis","volume":"34","author":"Wallach","year":"2019","journal-title":"J Gen Intern Med"},{"key":"2025081402301320000_10.8.e018517.17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoncol.2021.6854","article-title":"Accelerated Approval Is Not Conditional Approval: Insights From International Expedited Approval Programs","volume":"8","author":"Mehta","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025081402301320000_10.8.e018517.18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33601","article-title":"Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018","volume":"4","author":"Wallach","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025081402301320000_10.8.e018517.19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s43441-023-00574-6","article-title":"Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations","volume":"58","author":"Ghadanian","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"2025081402301320000_10.8.e018517.20","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306273"},{"key":"2025081402301320000_10.8.e018517.21","unstructured":"United Nations . WHO declares mpox virus a public health emergency of international concern. Available: https:\/\/news.un.org\/en\/story\/2024\/08\/1153176 [Accessed 3 Dec 2024]."},{"key":"2025081402301320000_10.8.e018517.22","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1016\/j.vaccine.2023.05.008","article-title":"Monkeypox, smallpox, FDA, and accelerated approval of vaccines \u2013 A regulatory perspective","volume":"41","author":"Sun","year":"2023","journal-title":"Vaccine (Auckl)"},{"key":"2025081402301320000_10.8.e018517.23","unstructured":"World Health Organization . Emergency use listing procedure. Available: https:\/\/extranet.who.int\/prequal\/medicines\/emergency-use-listing-procedure [Accessed 16 Jun 2025]."},{"key":"2025081402301320000_10.8.e018517.24","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jama.2020.16253","article-title":"Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval","volume":"324","author":"Thomson","year":"2020","journal-title":"JAMA"},{"key":"2025081402301320000_10.8.e018517.25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40290-021-00397-6","article-title":"The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic","volume":"35","author":"Tran","year":"2021","journal-title":"Pharm Med"},{"key":"2025081402301320000_10.8.e018517.26","unstructured":"US Food and Drug Administration . Emergency Use Authorization, 2024. Available: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization [Accessed 3 Dec 2024]."},{"key":"2025081402301320000_10.8.e018517.27","unstructured":"European Medicines Agency . Conditional marketing authorisation. Available: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/conditional-marketing-authorisation [Accessed 3 Dec 2024]."},{"key":"2025081402301320000_10.8.e018517.28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(21)00085-4","article-title":"The European Medicines Agency\u2019s EU conditional marketing authorisations for COVID-19 vaccines","volume":"397","author":"Cavaleri","year":"2021","journal-title":"The Lancet"},{"key":"2025081402301320000_10.8.e018517.29","unstructured":"Pharmaceuticals and medical devices agency. Available: https:\/\/www.pmda.go.jp\/english\/index.html [Accessed 3 Dec 2024]."},{"key":"2025081402301320000_10.8.e018517.30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cpt.2310","article-title":"Japan\u2019s Special Approval for Emergency System During the COVID\u201019 Pandemic","volume":"111","author":"Maeda","year":"2022","journal-title":"Clin Pharma and Therapeutics"},{"key":"2025081402301320000_10.8.e018517.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309992","article-title":"Comparison of regulatory approval system for medicines in emergency among Japan, the United States, the United Kingdom, Europe, and China","volume":"19","author":"Edo","year":"2024","journal-title":"PLoS One"},{"key":"2025081402301320000_10.8.e018517.32","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jama.2020.17101","article-title":"Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency","volume":"324","author":"Avorn","year":"2020","journal-title":"JAMA"},{"key":"2025081402301320000_10.8.e018517.33","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025081402301320000_10.8.e018517.34","doi-asserted-by":"crossref","unstructured":"Parums DV . Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy. Med Sci Monit 2021;27. doi:10.12659\/MSM.934625","DOI":"10.12659\/MSM.934625"},{"key":"2025081402301320000_10.8.e018517.35","doi-asserted-by":"crossref","unstructured":"Krause PR , Gruber MF . Emergency Use Authorization of Covid Vaccines \u2014 Safety and Efficacy Follow-up Considerations. N Engl J Med 2020;383. doi:10.1056\/NEJMp2031373","DOI":"10.1056\/NEJMp2031373"},{"key":"2025081402301320000_10.8.e018517.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.02.016"},{"key":"2025081402301320000_10.8.e018517.37","doi-asserted-by":"crossref","unstructured":"Cerda AA , Garc\u00eda LY . Hesitation and Refusal Factors in Individuals\u2019 Decision-Making Processes Regarding a Coronavirus Disease 2019 Vaccination. Front Public Health 2021;9. doi:10.3389\/fpubh.2021.626852","DOI":"10.3389\/fpubh.2021.626852"},{"key":"2025081402301320000_10.8.e018517.38","unstructured":"Coalition for Epidemic Preparedness Innovations . CEPI 2.0 and the 100 days mission. Available: https:\/\/cepi.net\/cepi-20-and-100-days-mission [Accessed 3 Dec 2024]."},{"key":"2025081402301320000_10.8.e018517.39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.clinthera.2022.01.001","article-title":"Rolling Reviews During COVID-19: The European Union Experience in a Global Context","volume":"44","author":"Marinus","year":"2022","journal-title":"Clin Ther"},{"key":"2025081402301320000_10.8.e018517.40","doi-asserted-by":"crossref","DOI":"10.1017\/cts.2023.537","article-title":"Recent innovations in adaptive trial designs: A review of design opportunities in translational research","volume":"7","author":"Kaizer","year":"2023","journal-title":"J Clin Trans Sci"},{"key":"2025081402301320000_10.8.e018517.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.06.005"},{"key":"2025081402301320000_10.8.e018517.42","first-page":"1","article-title":"Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes","volume":"85","author":"Rizk","year":"2025","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025081402301320000_10.8.e018517.43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1126\/science.adw1657","article-title":"Mpox drug wins approval in Japan\u2014but it doesn\u2019t work","volume":"387","author":"Cohen","year":"2025","journal-title":"Science"},{"key":"2025081402301320000_10.8.e018517.44","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-120014564"},{"key":"2025081402301320000_10.8.e018517.45","doi-asserted-by":"crossref","unstructured":"Topaloglu U , Palchuk MB . Using a Federated Network of Real-World Data to Optimize Clinical Trials Operations. JCO Clinical Cancer Informatics 2018;1\u201310. doi:10.1200\/CCI.17.00067","DOI":"10.1200\/CCI.17.00067"},{"key":"2025081402301320000_10.8.e018517.46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12869","article-title":"Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence","volume":"2","author":"Bartlett","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025081402301320000_10.8.e018517.47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.drudis.2018.07.005","article-title":"Streamlining nonclinical drug development using the FDA 505(b)(2) new drug application regulatory pathway","volume":"24","author":"Salminen","year":"2019","journal-title":"Drug Discov Today"},{"key":"2025081402301320000_10.8.e018517.48","first-page":"403","article-title":"The 505(b)(2) Drug Approval Pathway","volume":"74","author":"Darrow","year":"2019","journal-title":"Food Drug Law J"},{"key":"2025081402301320000_10.8.e018517.49","unstructured":"Lezotre PL . International cooperation, convergence and harmonization of pharmaceutical regulations: a global perspective. Academic Press, 2013."},{"key":"2025081402301320000_10.8.e018517.50","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.vaccine.2020.11.077","article-title":"Regulatory Harmonization and Streamlining of Clinical Trial Applications globally should lead to faster clinical development and earlier access to life-saving vaccines","volume":"39","author":"Scheppler","year":"2021","journal-title":"Vaccine (Auckl)"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2024-018517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T09:30:27Z","timestamp":1755163827000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2024-018517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,14]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjgh-2024-018517"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2024-018517","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}